Live webcast fireside chat on Wednesday, March 30th at 2:30 PM ET
HOUSTON, March 23,
2022 /PRNewswire/ -- CNS Pharmaceuticals, Inc.
(NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical
company specializing in the development of novel treatments for
primary and metastatic cancers in the brain and central nervous
system, today announced that John
Climaco, CEO of CNS Pharmaceuticals will participate at the
2022 Virtual Growth Conference presented by Maxim Group LLC and
hosted by M-Vest, taking place March 28-30,
2022.
In addition to the Company's corporate presentation available on
demand for registered attendees, Mr. Climaco will participate in a
live fireside chat moderated by Jason
McCarthy, PhD, Head of Biotechnology Research at Maxim
Group, on Wednesday, March 30, 2022,
at 2:30 PM ET.
During this virtual conference, investors will hear from
executives from a wide range of sectors including Biotech, Clean
Energy, Electric Vehicles, Financial Services, Fintech & REITS,
Gaming & Entertainment, Healthcare, Healthcare IT,
Infrastructure, Shipping and Technology/ Media/Telecom. The
conference will feature company presentations, fireside chats,
roundtable discussions, and live Q&A with CEOs moderated by
Maxim Research Analysts.
This conference will be live on M-Vest. To attend, just sign up
to become an M-Vest member.
Click Here to Reserve Your Seat
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company
developing a pipeline of anti-cancer drug candidates for the
treatment of primary and metastatic cancers of the brain and
central nervous system. The Company's lead drug candidate,
Berubicin, is a novel anthracycline and the first anthracycline to
appear to cross the blood-brain barrier. Berubicin is currently in
development for the treatment of a number of serious brain and CNS
oncology indications including glioblastoma multiforme (GBM), an
aggressive and incurable form of brain cancer.
Additionally, the Company is advancing the development of its
WP1244/WP1874 drug technology, which utilizes anthracycline and
distamycin-based scaffolds to create small molecule agents and is
believed to be 500x more potent than daunorubicin in inhibiting
tumor cell proliferation. Preclinical studies of WP1244
demonstrated high uptake in the brain with antitumor activity. CNS
Pharmaceuticals is also evaluating the use of WP1244/WP1874 in the
treatment of other primary brain and central nervous system
cancers, as well as cancers metastatic to the brain including
pancreatic, ovarian, and lymphomas.
For more information, please visit www.CNSPharma.com, and
connect with the Company on Twitter, Facebook, and LinkedIn.
Forward-Looking Statements
Some of the statements in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, CNS's ability to continue to
recruit patients for its potentially pivotal study to evaluate
efficacy of Berubicin in the treatment of adult GBM; and CNS's
ability to complete enrollment in the potentially pivotal clinical
trial for GBM. These statements relate to future events, future
expectations, plans and prospects. Although CNS believes the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties and
other factors, including those discussed under Item 1A. "Risk
Factors" in CNS's most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in its Form 10-Q filings and in its other public filings with
the SEC. Any forward-looking statements contained in this press
release speak only as of its date. CNS undertakes no obligation to
update any forward-looking statements contained in this press
release to reflect events or circumstances occurring after its date
or to reflect the occurrence of unanticipated events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-participate-in-the-2022-virtual-growth-conference-presented-by-maxim-group-llc-and-hosted-by-m-vest-301508467.html
SOURCE CNS Pharmaceuticals, Inc.